Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Wednesday, September 17, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Price reaction · baseline $6.2 (2025-09-16 close) · hit after-hours · 1 other SGMT headline(s) in the window, move may be shared
day 0 close
-0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025.